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The passage of compounds from the systemic blood into the central nervous system (CNS) is limited by the presence of the capillary endothelial cells of the blood-brain barrier (BBB).
Two important functions of the BBB are the protection of the brain against potentially toxic substances and the maintenance of a constant internal environment, which is of primary importance to the optimal neuronal functioning of the brain. The barrier has cellular tight junctions and express transport systems which serve active passage into the brain, and active efflux out of the brain (Ballabh et al., 2004) .
One of the most studied transport proteins is P-glycoprotein (P-gp) which is a product of the multidrug resistance (MDR) gene MDR1 (also known as ABCB1). P-gp is a membrane-bound ATP-dependent efflux transporter present at high concentrations in the apical membrane of the endothelial cells of the brain capillaries (Beaulieu et al., 1997; Biegel et al., 1995) . P-gp and other drug transporters have significant effects on absorption, distribution, metabolism and excretion of drugs. These effects are especially apparent when oral bioavailability and the CNS distribution of several drugs are considered (Fromm, 2000) . This is even more important as no structural similarity between the P-gp substrates has been found that would allow predicting new substances that may be P-gp substrates. The P-gp substrates include anticancer agents, immunosuppressants, steroid hormones, antimicrobial agents, opioids and CNS active drugs (Fromm, 2002) .
The prescribing of antipsychotic and antidepressant drugs has increased appreciably during the past decade (Pirraglia et al., 2003; Sonnenberg et al., 2008) . One example of such a drug is the antidepressant venlafaxine, a potent serotonin and noradrenalin reuptake inhibitor with some effect also on dopamine reuptake (Ellingrod and Perry, 1994) . Venlafaxine is a racemic 4 mixture of the (-)-R-enantiomer and (+)-S-enantiomer. The R-enantiomer inhibits both serotonin and noradrenaline reuptake in vitro, while the S-enantiomer inhibits only serotonin reuptake (Holliday and Benfield, 1995; Muth et al., 1986) . Venlafaxine undergoes extensive first-pass metabolism by cytochrome P450 (CYP) enzymes into its major active metabolite Odesmethylvenlafaxine (Odm-venlafaxine). Two minor metabolites are Ndesmethylvenlafaxine (Ndm-venlafaxine) and N,O-didesmethylvenlafaxine (Ddmvenlafaxine). Odm-venlafaxine inhibits reuptake of serotonin and noradrenaline with similar potency to that of venlafaxine, but no data are available on the relative efficiency of the two enantiomers. Ndm-venlafaxine and Ddm-venlafaxine may also be considered as pharmacologically active, but they are claimed to be less potent than the parent drug (Muth et al., 1986; Muth, 1991) .
Between individuals the results of drug therapy can vary depending on the efficiency of the Pgp ABCB1 gene owing to various polymorphisms among individuals leading to different drug levels and therapy outcome (Linnet and Ejsing, 2008; Uhr et al., 2008) . Consequences of drug efflux transporters, like P-gp, in the BBB include limiting the distribution of substances that are beneficial to treat psychiatric disorders, and increasing the problem of drug-drug interactions and potential toxicity. The importance of P-gp in the BBB has been studied extensively in cultured mammalian brain capillary endothelial cells (Tsuji et al., 1992) .
However, the in vitro models cannot completely represent the complex in vivo situation. To overcome this problem, transgenetic mice can be used. In humans, P-gp is encoded by a single ABCB1 gene, whereas two genes, abcb1a and abcb1b, encode P-gp in mice (Devault and Gros, 1990) . The abcb1ab knockout mouse was developed to investigate the role of P-gp in vivo and has provided a unique and valuable pharmacological tool (Lagas et al., 2009; Schinkel et al., 1997; Schinkel et al., 1994 ). This animal model shows that venlafaxine is a P-5 gp substrate (Doran et al., 2005; . However, no studies have examined the role of P-gp on possible stereoselective differences in the disposition of venlafaxine and its three main metabolites in the brain. Such knowledge is important since the enantiomers of venlafaxine display different pharmacological activities in vitro. Whether Odm-venlafaxine, Ndm-venlafaxine and Ddm-venlafaxine are P-gp substrates has not previously been reported.
Therefore, the aim of this study was to determine whether the brain uptake of the S-and Renantiomers of venlafaxine, Odm-venlafaxine, Ndm-venlafaxine and Ddm-venlafaxine differs between abcb1ab knockout mice and corresponding wildtype mice.
Experimental procedures

Animals
All experiments were conducted in accordance with the European guidelines for care and use of laboratory animals and approved by local authorities. Male abcb1ab (-/-) mice (31-35 g) on a FVB/N background (Taconic, Germantown, NY) and male FVB/N wildtype mice (abcb1ab (+/+)) (31-33 g) were housed in groups of 3-5 in cages with sawdust bedding under normal indoor temperature and humidity, and maintained on 12-hour light-dark cycle, with food and water ad libitum.
Drugs and Chemicals
Racemic venlafaxine-HCl (kindly provided by Wyeth-Ayerst Research, Rouses Point, VT, USA) was dissolved in 0.9% NaCl and administered intraperitoneally (i.p.). All other chemicals were of the purest grade commercially available.
Experimental design
Venlafaxine was administered to abcb1ab (-/-) knockout (n=10 per time point) and abcb1ab (+/+) FVB/N wildtype (n=10 per time point) mice by a single i.p. injection during a brief anesthesia with isoflurane (Forene®, Abbott GmbH & Co. KG, Wiesbaden, Germany). The 6 concentration used was 10 mg/kg body weight and the total volume injected was 1 mL. At four different time points (1, 3, 6 and 9 hours) following drug administration, the mice were anesthetized with isoflurane and decapitated. Trunk blood was collected in tubes and thereafter the brain was removed. The blood samples were left at room temperature to allow clotting and thereafter centrifuged (3000g for 5 min x 2). Serum was collected for the determination of the concentrations of the enantiomers of venlafaxine and its three main metabolites. All samples were frozen at -70°C until further analysis.
Drug extraction procedure
Venlafaxine and metabolites were extracted from serum and brain by a solid-phase extraction (SPE) procedure. The brain samples were weighed and homogenized in 2 mL ultra pure water using a sonifier (Sonics VibraCell VC 130; Chemical Instruments AB, Lidingö, Sweden) followed by centrifugation (2000g for 20 min). The Isolute C8 100 mg (International Sorbent Technology, Hengoed, UK) SPE column was conditioned with methanol and Milli-Q water. Thereafter, 0.2 mL of calibration standard, control, brain homogenate or serum sample, and 20 µL of the internal standard mexiletine (0.05 mmol/L), was added. After washing with 1 mL Milli-Q water, followed by 2 mL of 50% methanol and 2 mL of acetonitrile, the sample was eluated with 1.5 mL acetonitrile containing 10 mM trifluoroacetic acid. The eluate was evaporated with nitrogen at 50°C in a block thermostat (Grant QBT2; Grant Instruments (Cambridge) Ltd, UK) and reconstituted in 50 µL of mobile phase (10:90 v/v; 10 mM tetrahydrofurane: ammonium acetat, pH 6.0) and transferred to a vial.
Drug concentration determination
The concentrations of the S-and R-enantiomers of venlafaxine and its metabolites in serum (nmol/L) and brain homogenates (pmol/g  nmol/L) were determined by using an Acquity liquid chromatography (LC) system (Waters, Milford, MA, USA) and a Sciex API 4000 tandem mass detector equipped with an electrospray ionization (ESI) ion source (PE Sciex, 7 Ontario, Canada). A volume of 5 µL reconstituted sample was injected onto a Chirobiotic-V column (5 µm particle size, 250 x 2.1 mm; Astec, Basle, Switzerland) protected with an inline filter (VICI AB International, Switzerland). The temperature of the column was set to 10°C using a Jones Chromatography Model 7955 column chiller/heater (Hengoed, UK) and the flow rate of the mobile phase was 0.2 mL/min. Formic acid (0.05%) in acetonitrile was delivered through a Gynkotek 480 pump (Dionex; Sunnyvale, CA, USA) and added post column at a flow rate of 0.2 mL/min to increase the sensitivity. Data acquisition and peak integration, recording the area of the peaks, were performed using Analyst 1 
Statistical analysis
Results are expressed as means ± standard error of the means (SEM). A two-tailed Student's t-test for unpaired observations was used to compare differences between groups. P values <0.05 were considered statistically significant. All statistical analyses were performed using StatView ® for Windows Version 5.0 (SAS ® Institute Inc., Cary, NC; USA).
Results
Concentrations of the enantiomers of venlafaxine and metabolites in brain
The concentrations of the S-and R-enantiomers of venlafaxine and its metabolites are displayed in Figure 1 . Table 1 shows the total (S+R) drug and metabolite concentrations as well as the concentration ratios between knockout and wildtype mice in serum and brain. In the brain, the S-and R-enantiomeric concentrations of venlafaxine were found to be 2-4 times higher in the abcb1ab knockout mice as compared to the wild type mice one, three and six hours following drug administration. No significant difference in venlafaxine concentrations was seen between the two groups nine hours post dose. For the main metabolite Odmvenlafaxine, the concentrations of the S-and R-enantiomers were 3-7 times higher in the knockout mice than in the wild type mice at all four time points (p<0.0001). The enantiomeric S-and R-Ndm-venlafaxine levels were 3-12 times higher in knockout mice as compared to wild type mice (p<0.0001 at all four time points). The concentrations of S-Ddm-venlafaxine were measurable one and three hours following drug administration in 90% and 50% of the abcb1ab knockout mice (concentration range 1.9-4.0 nmol/L and 1.6-2.2 nmol/L, respectively). R-Ddm-venlafaxine could only be measured after one hour in two out of ten of the abcb1ab knockout mice. The levels of Ddm-venlafaxine in the brain were below the limit of quantification for all the wildtype mice (data not shown).
Concentrations of the enantiomers of venlafaxine and metabolites in serum
One and three hours following drug administration, no significant differences were observed in the S-and R-enantiomeric concentrations of venlafaxine, Odm-venlafaxine and Ndmvenlafaxine in the knockout mice as compared to the wild type mice (exception for S-Odmvenlafaxine at 3 hours; Figure 1 and Table 1 ). The S-and R-concentrations of venlafaxine,
Odm-venlafaxine and Ndm-venlafaxine were found to be about 2 times higher in the abcb1ab knockout mice than in the wild type mice six hours following drug administration (p<0.001, p<0.01 and p<0.01, respectively). The S-and R-Ddm-venlafaxine concentrations were around the same in the two groups one and three hours following drug administration (data not shown). The serum levels of Ddm-venlafaxine were below the limit of quantification for the two later time points in both the abcb1ab knockout mice and the wildtype mice.
S/R concentration ratios of venlafaxine and metabolites
The enantiomeric S/R concentration ratios of venlafaxine, Odm-venlafaxine and Ndmvenlafaxine in serum and brain at four different time points after drug administration in abcb1ab knockout mice and wildtype mice are shown in Table 2 . For venlafaxine, the S/R ratios in brain were somewhat lower in P-gp deficient mice (~1.1-1.3) as compared to wildtype mice (~1.4-1.5) and this difference was statistically significant one, three and six hours following drug administration (p<0.001, p<0.01 and p<0.05, respectively). However, the knockout/wildtype ratios for the S-to R-enantiomers in brain were not different one, three and six hours post dose (2.1, 2.9 and 2.6 for S-venlafaxine vs. 2.7, 3.6 and 3.0 for Rvenlafaxine, respectively). In serum, no significant differences in venlafaxine S/R ratios were observed between abcb1ab knockout mice and wild type mice. The S/R ratios of Odmvenlafaxine and Ndm-venlafaxine were not significantly different between abcb1ab knockout and wildtype mice in the brain with two exceptions (Odm-venlafaxine at the 9 hour time point and Ndm-venlafaxine at the 1 hour time point).
Brain/serum concentration ratios of venlafaxine and metabolites
The brain/serum concentration ratios of venlafaxine, Odm-venlafaxine and Ndm-venlafaxine are displayed in Figure 2 . In mice lacking functional P-gp, the brain/serum ratio of venlafaxine were significantly higher compared to wild type mice at all four time points (1, 3, 6 and 9 h) after injection of racemic venlafaxine (p<0.01, p<0.0001, p<0.05 and p<0.05, 10 respectively). At the corresponding time points, the brain/serum concentration ratios of Odmvenlafaxine were found to be 3-4 times higher in the abcb1ab knockout mice as compared to the wild type mice (p-values ranging between p<0.01 to p<0.0001). One to nine hours post dose, the brain/serum concentrations ratios of Ndm-venlafaxine were higher in the abcb1ab knockout mice as compared to the wild type mice (p-values ranging between p<0.001 to p<0.0001).
Metabolite/Parent drug ratios in serum and brain
The metabolite/parent drug (M/P) ratios for Odm-venlafaxine/venlafaxine in serum were similar between the two groups at one, three and six hours post dose ( 
Discussion
We show for the first time data on the disposition of the enantiomers of venlafaxine and its metabolites in the P-gp knockout mouse model. The results of this study demonstrate that Pgp decreases the brain uptake of the S-and R-enantiomers of venlafaxine as well as the main metabolites (Odm-venlafaxine and Ndm-venlafaxine). This was confirmed from the observation of higher brain concentrations of venlafaxine and the metabolites Odmvenlafaxine and Ndm-venlafaxine in the abcb1ab (-/-) mice as compared to the abcb1ab (+/+) mice. Furthermore, we saw no evidence of a stereoselective P-gp mediated transport of 11 these substances over the BBB. This finding is important since it has been reported that the enantiomers of venlafaxine display different potencies of serotonin and noradrenaline reuptake inhibition in vitro. However, data on differential clinical properties of S-and Rvenlafaxine are lacking.
In accordance with , the brain concentration of venlafaxine was significantly higher in the knockout mice compared to wildtype mice. The present serum and brain knockout/wildtype ratios were 1.1 and 2.4, respectively, compared to 1.3 and 2.3 in the study by Uhr and co-workers . However, in their study they measured total (i.e. the sum of the S-and R-enantiomers; S+R) concentrations of venlafaxine and one metabolite (Ndm-venlafaxine) one hour after s.c. administration of racemic venlafaxine. In our study, the separate enantiomers of venlafaxine, and its three main metabolites (Odm-venlafaxine, Ndmvenlafaxine and Ddm-venlafaxine) were measured at four different time points (1, 3, 6 and 9 hours after i.p. injection). The results in the present study are also in line with the results reported by Doran and co-workers although they investigated the total (S+R) concentration of venlafaxine (Doran et al., 2005) . One hour after drug administration, the brain/serum concentrations of venlafaxine in knockout mice were 10 vs. 7.7 and the corresponding ratios in wildtype mice were 4.3 vs. 4.2 (present study vs. Doran et al., 2005 Rochat and co-workers reported that citalopram crosses the BBB without the influence of Pgp (Rochat et al., 1999) . By contrast, used the abcb1ab knockout mouse model to show that citalopram is actively transported out of the brain by P-gp and similar results were found by Doran et al. (2005) . In vivo models like the use of abcb1ab knockout mouse have an additional advantage, namely that they allow studies of pharmacokinetic interactions as well as pharmacodynamic effects (Kirschbaum et al., 2008) .
To this end, Schinkel and co-workers showed that complete loss of P-gp does not lead to any marked physiological abnormalities, and that the abcb1ab knockout mouse thus provide a good model to study the roles of P-gp in pharmacology and toxicology (Schinkel et al., 1997) .
In the present study, we also investigated the disposition of the S-and R-enantiomers of venlafaxine and its metabolites in serum and brain. The serum venlafaxine S/R concentration ratios were 1.2-1.4 in abcb1ab (-/-) mice and 1.1-1.3 in abcb1ab (+/+) mice, but this difference was not statistically significant. Similarly, no significant differences in S/R concentration ratios for Odm-venlafaxine or Ndm-venlafaxine were observed in serum or brain between knockout and wildtype mice. In contrast, significant differences in venlafaxine brain S/R concentration ratios were observed between knockout and wildtype mice with a somewhat lower S/R ratio in knockout mice. However, when comparing the 13 knockout/wildtype ratios for the S-to R-enantiomers in brain no differences in enantiomeric concentrations between the two groups were found. These data suggest that the P-gp affinity does not differ between the enantiomers of venlafaxine, Odm-venlafaxine or Ndm-
venlafaxine. An absence of stereoselective P-gp mediated transport has also been found for R/S-verapamil (Luurtsema et al., 2003; Sandstrom et al., 1998) . In contrast to our findings, a stereoselectivity for R/S-methadone in the abcb1ab (-/-) mouse model was reported in which the brain knockout/wildtype ratios of R-and S-methadone were 15.3 and 23.5, respectively (Wang et al., 2004) . The pharmacokinetics of fexofenadine was also shown to display stereoselectivity with a higher P-gp affinity for the S-enantiomer than for the R-enantiomer (Miura et al., 2007) . However, measuring the concentrations of enantiomers when steady-state conditions are reached might give results more closely related to the situation in humans, in which drugs are given over longer periods. This might be one limitation with the present study and more work is necessary to assess the role of P-gps in chiral discrimination.
Chiral considerations are relevant to various aspects of pharmacology and toxicology.
Stereoselective metabolism of chiral drugs can additionally influence pharmacokinetics, pharmacodynamics and toxicity (Smith, 2009 ). To our knowledge, no published data in mice are available to compare with the present results. In dogs, the mean plasma S/R concentration ratios of venlafaxine were 1.5 (chronic administration of 22 mg/kg/day) and in rats 5.5
(chronic administration of 120 mg/kg/day) (Wang et al., 1992) . In another rat model the S/R venlafaxine ratio in serum was 1.4 after chronic administration of racemic venlafaxine (Wikell et al., 2002) . In humans, a mean plasma S/R enantiomeric ratio of 1.3 (n=9) was reported after a single 50 mg dose of racemic venlafaxine (Wang et al., 1992 ). Eap and coworkers published a case report with a patient displaying a serum S/R venlafaxine ratio of 1.9 (Eap et al., 2000) . Gex-Fabry et al. investigated 35 patients on chronic medication with 14 venlafaxine and they reported S/R concentration ratios between 0.4-2.5 (median 1.1) (GexFabry et al., 2004; Gex-Fabry et al., 2002) . Ciusani and co-workers studied 5 patients receiving individually adapted doses between 75-225 mg/day and they found mean plasma S/R ratios of 1.16, 0.94 and 1.01 for venlafaxine, Odm-venlafaxine and Ndm-venlafaxine, respectively (Ciusani et al., 2004) . Taken together, there seems to be both species differences and inter-individual variability in the S/R disposition that need to be considered when results from different studies are compared. One also has to consider how the drug was administered and the time of sampling in relation to the time when the drug was given.
In the present study, a stereoselective disposition of Odm-venlafaxine and Ndm-venlafaxine in both knockout mice and wildtype mice was found. This stereoselectivity is probably due to a stereoselective metabolism of venlafaxine by the CYP-enzymes. Venlafaxine is metabolized by CYP2D6 to its main metabolite Odm-venlafaxine and by CYP3A4 to Ndm-venlafaxine.
The metabolite Ndm-venlafaxine is then further metabolized to Ddm-venlafaxine, possibly by CYP2D6 (Fogelman et al., 1999; Muth et al., 1986; Muth, 1991; Otton et al., 1996) . Although CYP2D6 metabolizes both the S-and R-enantiomers of venlafaxine to Odm-venlafaxine it has been suggested that this enzyme is stereoselective. In humans, stereoselective metabolism of venlafaxine by CYP2D6 was reported but there was no evidence that this was the case for CYP3A4 (Eap et al., 2003) .
Uhr and co-workers were the first to suggest a relationship between genetic variants in the ABCB1 gene and the clinical efficacy of antidepressants, most likely by influencing their access to the brain (Uhr et al., 2008) . Such an observation might apply to other medications as well. For example, it has recently been reported in a clinical study that ABCB1 polymorphism influences the pharmacokinetics of the antipsychotic drug clozapine (Jaquenoud Sirot et al., 2009 ). However, whether this finding correlates with the clinical response requires further studying. Nevertheless, the investigation of transporters like P-gp remains highly relevant especially as no structural similarity between the P-gp substrates exists. It is a necessity that therapeutic levels of drugs reach the brain in order to treat CNS disorders like major depression. Since P-gp and other ATP-binding cassette (ABC) transporters can limit the transport of drugs into the brain (Deeley et al., 2006) all CNS drugs needs to be tested with regard to interactions with these transport proteins.
Another point of clinical relevance for P-gp substrates is co-medication and the possibility of drug interactions. Some substances can increase the expression of P-gp and one example is the herbal antidepressant treatment St. John's Wort (Hennessy et al., 2002) . Such an interaction was reported for venlafaxine in an in vitro study (Ehret et al., 2007) . So either the medication itself or the co-medication possibly influences the treatment results via modulation of P-gp. This might explain why some patients do not reach sufficient drug concentrations in the brain and therefore fail to benefit from therapy. A number of substances have successfully been used to decrease (Ford and Hait, 1990) or increase the P-gp activity in cell cultures and animal experiments (Seelig, 1998) . It can therefore be assumed that co-medications may counteract therapeutic effects in humans, explaining inter-individual differences in response to drugs that are substrate for P-gp.
In conclusion, the two major novel findings of the present study are that: (1) the S-and Renantiomers of venlafaxine and its two main metabolites (Odm-venlafaxine and Ndmvenlafaxine) are substrates for P-gp, and (2) the P-gp affinity does not differ between the two enantiomers of venlafaxine or the metabolites. Accordingly, the present results confirm and extend previously obtained pharmacokinetic data on venlafaxine in the P-gp knockout mouse model. Since several CNS-active drugs are given as racemic mixtures further research is warranted to predict the interaction of such drugs with P-gp at the BBB and thereby improve drug safety and therapeutics.
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